Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct;53(10):4292-7.
doi: 10.1128/AAC.01664-08. Epub 2009 Jul 27.

Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection

Affiliations

Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection

Nicolas Allou et al. Antimicrob Agents Chemother. 2009 Oct.

Abstract

We investigated the impact of low-level resistance to fluoroquinolones on the bactericidal activity of ciprofloxacin in a murine model of urinary tract infection. The susceptible Escherichia coli strain CFT073 (ciprofloxacin MIC [CIP MIC] of 0.008 microg/ml) was compared to its transconjugants harboring qnrA1 or qnrS1 and to an S83L gyrA mutant. The three derivatives showed similar low-level resistance to fluoroquinolones (CIP MICs, 0.25 to 0.5 microg/ml). Bactericidal activity measured in vitro after 1, 3, and 6 h of exposure to 0.5 microg/ml of ciprofloxacin was significantly lower for the derivative strains (P < 0.01). In the murine model of urinary tract infection (at least 45 mice inoculated per strain), mice were treated with a ciprofloxacin regimen of 2.5 mg/kg, given subcutaneously twice daily for 2 days. In mice infected with the susceptible strain, ciprofloxacin significantly decreased viable bacterial counts (log10 CFU/g of tissue) in the bladder (4.2 +/- 0.5 versus 5.5 +/- 1.3; P = 0.001) and in the kidney (3.6 +/- 0.8 versus 5.0 +/- 1.1; P = 0.003) compared with those of untreated mice. In contrast, no significant decrease in viable bacterial counts was observed with any of the three derivative strains. The area under the concentration-time curve from 0 to 24 h/MIC and the maximum concentration of drug in serum/MIC ratios measured in plasma were indeed equal to 827 and 147, respectively, for the parental strain, and only 12.4 to 24.8 and 2.2 to 4.4, respectively, for the derivative strains. In conclusion, low-level resistance to fluoroquinolones conferred by a qnr gene is associated with decreased bactericidal activity of ciprofloxacin, similar to that obtained with a gyrA mutation.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Bactericidal activity of ciprofloxacin at a concentration of 0.5 μg/ml against the four different E. coli strains. P was <0.01 after 1, 3, and 6 h of incubation for any of the three strains with low-level of resistance compared with the susceptible E. coli CFT073-RR strain. P was <0.05 for E. coli CFT073-RR Tc (pQnrS1) and E. coli CFT073-RR-gyrA and 0.07 for E. coli CFT073-RR Tc (pQnrA1) compared with E. coli CFT073-RR after 24 h of incubation.
FIG. 2.
FIG. 2.
Bactericidal activity of ciprofloxacin at a concentration that was four times the MIC of each of the E. coli study strains. P was >0.2 at all times for the three strains with low-level resistance compared with the susceptible E. coli CFT073-RR strain.

References

    1. Blondeau, J. M., X. Zhao, G. Hansen, and K. Drlica. 2001. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:433-438. - PMC - PubMed
    1. Brunner, M., H. Stab, J.-G. Möller, C. Schrolnberger, B. Erovic, U. Hollenstein, M. Zeitlinger, H. G. Eichler, and M. Müeller. 2002. Target site concentrations of ciprofloxacin after single intravenous and oral doses. Antimicrob. Agents Chemother. 46:3724-3730. - PMC - PubMed
    1. Cambau, E., C. Lascols, W. Sougakoff, C. Bebear, R. Bonnet, J. D. Cavallo, L. Gutmann, M. C. Ploy, V. Jarlier, C. J. Soussy, and J. Robert. 2006. Occurrence of qnrA-positive clinical isolates in French teaching hospitals during 2002-2005. Clin. Microbiol. Infect. 12:1013-1020. - PubMed
    1. Cesaro, A., R. R. Bettoni, C. Lascols, A. Merens, C. J. Soussy, and E. Cambau. 2008. Low selection of topoisomerase mutants from strains of Escherichia coli harbouring plasmid-borne qnr genes. J. Antimicrob. Chemother. 61:1007-1015. - PubMed
    1. Chenia, H. Y., B. Pillay, and D. Pillay. 2006. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. J. Antimicrob. Chemother. 58:1274-1278. - PubMed

Publication types

MeSH terms